Summary of HOME III outcomes Full HOME III meeting minutes
The following presentations were given at the meeting - please feel free to use these, however, if you require a powerpoint version, please contact us at HOME@nottingham.ac.uk
Presentation 1.1 - Introduction and Background
Hywel Williams
Presentation 1.2 - The Gift of the OMERACT filter
Jasvinder Singh
Presentation 1.3 - Feasibility in all settings
Kim Thomas
Presentation 1.4 - The use of Global Assessments in Atopic Dermatitis Research - A Systematic Review of Randomized Controlled Trials.
Masutaka Futamura, Kim Thomas, Helen Nankervis, Joanne Chalmers, Hywel Williams and Eric Simpson
Presentation 2.1 - Measuring responsiveness (sensitivity to change) and minimally clinically important difference (MCID) of the Three Item Severity scales (TIS).
Mandy Schram, Phyllis Spuls, Kim Thomas and Jochen Schmitt
Presentation 2.2 - Measurement properties of outcome measurements for atopic dermatitis.
Jochen Schmitt, Stefanie Deckert, Sinead Langan, Ake Svensson, Laura von Kobyletzki, Kim Thomas and
Phyllis Spuls.
Presentation 3.1 - Quality of Life (QoL) Measures in Atopic Dermatitis Clinical Care and Research
Shehla Admani and Magdalene Dohil
Presentation 3.2 - Measurement properties of eczema-specific measures of health-related quality of life: systematic review
Christian Apfelbacher
Presentation 4.1 - The Use of Symptom Outcome Measures in Atopic Dermatitis Research - a Systematic Review of Randomized Controlled Trials
Joanne Chalmers, Helen Nankervis, Kim Thomas and Phyllis Spuls
Presentation 4.2 - Eczema Signs and Symptoms: what is important to patients?
Laura von Kobyletzki, Ake Svensson, Jochen Schmitt and Kim Thomas
Presentation 4.3 - Comparison of VAS and verbal rating scale in Japanese patients using VAS with 10 point end of "worst imaginable itch".
Norito Katoh, Makiko Nakahara, Hidehisa Saeki, Akihito Hagihara, Hitoshi Mizutani and Masutaka Furue
Please note the following three presentations have been combined into one document:
Presentation 5.1 - Systematic review of flare definitions used in prospective studies. "How should atopic dermatitis 'flares' be defined?" Implications for the design and conduct of trials.
Sinead Langan, Kim Thomas, Jochen Schmitt, Sherie Smith and Hywel Williams
Presentation 5.2 - A Validation study of a flare definition based on the need to escalate treatment as a result of worsening disease control.
Kim Thomas, Beth Stuart, Jochen Schmitt, Sinead Langan, Carle Paul and Hywel Williams
Presentation 5.3 - Validation Study of well-controlled weeks as a way of measuring long-term control.
Kim Thomas, Beth Stuart, Jochen Schmitt, Sinead Langan, Carle Paul and Hywel Williams
The HOME III working meeting was held in San Diego, USA in April 2013 and was attended by 56 individuals (representing patients, clinicians, methodologists and the pharmaceutical companies) from 10 countries.
Consensus was reached that the EASI is the recommended instrument for clinician-reported signs in eczema trials. All future trials should include EASI. However, the inclusion of this core outcome measure for clinical signs does NOT exclude the use of other clinical signs scales as needed for individual trials. Also, there is no requirement for a core outcome to be a primary outcome. Including the core measure in the assessments will mean that all future trials will be able to be combined effectively in meta-analyses.
Progress was made on the patient-reported symptoms, quality of life and long term control domains. Progression in identifying core instruments for these domains will be the focus of the HOME IV meeting in April 2015.
Publications
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema / dermatitis clinical trials (HOME)
Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M, Chalmers J, Williams HC.
Br J Dermatol. 2014 Dec;171(6):1318-25. doi: 10.1111/bjd.13237 (Abstract Link)
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
Schmitt J, Spuls PI, thomas KS, Simpson E, Furue M, Deckert S, Dohil M, Apfelbacher C, Singh JA, Chalmers J, Williams HC; HOME initiative collaborators.
J Allergy Clin Immunol 2014 Oct;134(4):800-7. doi: 10.1016/j.jaci.2014.07.043 (Abstract Link)